Document 0843
 DOCN  M9440843
 TI    [Survival of patients with zidovudine resistant HIV]
 DT    9404
 AU    Gotzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF;
       Epidemiafdeling M, Rigshospitalet, Kobenhavn.
 SO    Ugeskr Laeger. 1994 Jan 10;156(2):185-6. Unique Identifier : AIDSLINE
       MED/94126958
 AB    The survival of 35 patients with AIDS or advanced HIV infection on
       zidovudine treatment was related to the viral sensitivity to the drug
       and to the CD4+ cell count. Fourteen patients died, the survivors were
       followed up for an average of 804 days. In a univariate Cox model,
       survival was strongly related to log IC90 (p = 0.0003) and to the CD4+
       count (p = 0.0002). In a bivariate model, log IC90 and the CD4+ count
       contributed to the prediction of survival (p = 0.12 and 0.06,
       respectively). Large studies of combination or alternation therapy with
       several anti-HIV-drugs should be given high priority.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY/IMMUNOLOGY/  *MORTALITY
       Adult  Cohort Studies  Double-Blind Method  Drug Resistance, Microbial
       English Abstract  Human  HIV Seropositivity/DRUG THERAPY/IMMUNOLOGY
       Leukocyte Count  Male  Prognosis  T4 Lymphocytes/IMMUNOLOGY
       Zidovudine/*THERAPEUTIC USE  CLINICAL TRIAL  JOURNAL ARTICLE  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).